ESTRO 2022 - Abstract Book

S497

Abstract book

ESTRO 2022

PIB were similar for patients with vs. without PAE (5.9±2.9 ng/ml vs. 6.2±2.8 ng/ml and 1.5±0.8 ng/ml vs. 1.9±1.5 ng/ml). However, PSA 12 months after PIB was significantly lower after PAE (0.4±0.3 ng/ml vs. 0.8±0.6 ng/ml; p=0.03). Four patients without prior PAE needed an intervention following urinary retention – transurethral resection of the prostate (TURP) in 3 cases and PAE in a single case. Urinary incontinence resulted in 2 cases following TURP Conclusion PAE can be successfully applied to decrease prostate volume and reduce urinary symptoms before PIB or as a treatment for urinary retention after PIB. A significantly lower PSA is promising for improved long-term cancer control

PD-0567 PSA nadir has a significant prognostic value after prostate Iodine brachytherapy

P. Fernandes 1 , S. garcia 1 , M. Trigo 1

1 IPO Porto, Brachytherapy, Porto, Portugal

Purpose or Objective Prostate cancer is the most prevalent cancer among men worldwide, with its incidence rising with increasing age. Iodine brachytherapy (I-125 BT) is a known and validated treatment option for selected patients. Several studies investigated clinical, demographic, dosimetric and biochemical parameters related with disease control in patients treat with I-125 BT. The purpose of this study is to evaluate the outcome for low and intermediate risk prostate cancer following I-125 BT, specifically if prostate-specific antigen nadir (nPSA) is an independent predictor of disease-free survival (DFS), overall survival (OS) or disease specific survival (DSS). Materials and Methods In the period from January 2013 and October 2016, 250 patients were treated with I-125 BT alone. Patients were divided into three PSA nadir subgroups: group A <0. 2ng/mL; group B 0. 21 – 1 ng/mL; group C >1 ng/mL Biochemical recurrence was defined according to the Phoenix Consensus criteria... The impact of nPSA on DFS, OS and DSS was assessed using log rank test for univariate analysis and Cox regression for multivariate analysis. Statistical analysis was performed with SPSSv27 and considered statistically significant if p <0.05. Results Median follow-up time was 79 months (39 – 105 months). Median nPSA was 0.5 ng/mL. A PSA nadir of ≤ 0.2 ng/ml, 0.21–1 ng/ml, and >1 ng/ml was reached by 81.2%, 16.8%, and 2% of patients, respectively. DFS at 5 years was 99.5%, 76.2% and 40%, respectively for the three groups (p<0.001). This relation of nPSA groups on DFS was confirmed in Cox multivariate analysis (p<0.001). There were no significant differences in OS or DSS for the three groups; neither in Log Rank (p=0.6; p=2.2 respectively) or Cox analysis (p=0.9; p=0.7 respectively. Conclusion This study demonstrated excellent control rates, DFS, and DSS of I-125 BT monotherapy, confirming its role as an effective treatment for selected cases. In our study, levels of nPSA after brachytherapy predicted long-term biochemical control both in univariate and multivariate analysis, namely increased control for nPSA values <0.2 ng/mL, and higher risk of recurrence for nPSA >1 ng/mL. A favourable outcome should be expected in patients that achieve PSA nadir levels of 0.2ng/mL or less. J. Guinot 1 , V. Gonzalez-Perez 2 , J. Casanova 3 , M.A. Santos 4 , V. De los Dolores 2 , A. La Rosa 4 , A. Sanchez-Rodriguez 2 , A. Laborda 4 , S. Canos 1 , V. Cotanda 2 , C. Guardino 2 , M.I. Tortajada 4 , L. Arribas 4 1 Foundation Instituto Valenciano de Oncologia (IVO), Radiation oncology, Valencia, Spain; 2 Foundation Instituto Valenciano de Oncologia (IVO), Radiation Physics, Valencia, Spain; 3 Foundation Instituto Valenciano de Oncologia (IVO), Urology, Valencia, Spain; 4 Foundation Instituto Valenciano de Oncologia (IVO), Radiation Oncology, Valencia, Spain Purpose or Objective Brachytherapy (BT) with Iodine-125 seeds is effective in low-risk prostate carcinoma, similar to other techniques, but with fewer side effects. In intermediate risk there are variable results and relapses increase in the long term. The 10-year biochemical relapse-free survival (BRFS) results are presented. Materials and Methods Between 2007 and 2016, 706 patients were treated with the real-time technique with the ProLink (BARD) © system. 145 Gy was administered to the prostate with exclusive BT and 108 Gy after 46 Gy of external radiotherapy (EBRT). Hormonal blocking was used in 19.3%. Results With a median follow-up of 96 months (24-163), the BRFS at 5 years and 10 years is 95% and 91.1%. In the 480 low risk cases it is 95.7% and 92.7% and in the 226 intermediate risk cases 92.7% and 88% (p <0.05). With combined treatment EBRT + BT, 133 cases (59%) of intermediate risk were treated, without differences with the cases of exclusive BT. Gleason 4 + 3 cases PD-0568 Long-term results of Iodine-125 seed brachytherapy in low and intermediate risk prostate carcinoma